Prevention of Insulin-dependent Diabetes: Where Are We Now?

Understanding diabetic teratogenesis: Wh

Understanding diabetic teratogenesis: Where are we now and where are we going?

✍ Sheller Zabihi; Mary R. Loeken 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

## Abstract Maternal pregestational diabetes (type 1 or type 2) poses an increased risk for a broad spectrum of birth defects. To our knowledge, this problem first came to the attention of the Teratology Society at the 14th Annual Meeting in Vancouver, B.C. in 1974, with a presentation by Lewis Hol

Where Are We Now

✍ Patterson, Glenn 📂 Fiction 📅 2020 🏛 Head of Zeus; Apollo 🌐 English ⚖ 216 KB 👁 3 views

_'No one is more acutely tuned to the heartbeat of Belfast than Glenn Patterson and no one is more skilled at capturing all its love and madness. He does so with both tenderness and humour' DAVID PARK._ When he unexpectly loses his job, Herbie struggles to find a purpose. His wife, the great love o

Where Are We Now?

✍ Glenn Patterson 📂 Fiction 📅 2020 🏛 Apollo;Head of Zeus 🌐 English ⚖ 216 KB 👁 2 views

_'No one is more acutely tuned to the heartbeat of Belfast than Glenn Patterson and no one is more skilled at capturing all its love and madness. He does so with both tenderness and humour' DAVID PARK._ When he unexpectly loses his job, Herbie struggles to find a purpose. His wife, the great love o

Society of surgical oncology fellowship

Society of surgical oncology fellowship training: Where we have been, where we are now, and where we are going

✍ Russell S. Berman; Scott H. Kurtzman; Mitchell C. Posner; Jeffrey E. Gershenwald 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Treatment of primary aldosteronism: Wher

Treatment of primary aldosteronism: Where are we now?

✍ Asterios Karagiannis 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 135 KB

Prevention of insulin-dependent diabetes

Prevention of insulin-dependent diabetes mellitus 1998

✍ Pozzilli, Paolo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 3 views

Recent advances in the understanding of the pathogenesis of insulin-dependent diabetes mellitus (IDDM) have led to the first trials of disease prevention in susceptible individuals. Two main trials (nicotinamide and insulin) are now running but first results will not be available before the turn of